JP2023503046A5 - - Google Patents

Info

Publication number
JP2023503046A5
JP2023503046A5 JP2022529007A JP2022529007A JP2023503046A5 JP 2023503046 A5 JP2023503046 A5 JP 2023503046A5 JP 2022529007 A JP2022529007 A JP 2022529007A JP 2022529007 A JP2022529007 A JP 2022529007A JP 2023503046 A5 JP2023503046 A5 JP 2023503046A5
Authority
JP
Japan
Prior art keywords
seq
nucleic acid
sequence
aav vector
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022529007A
Other languages
English (en)
Japanese (ja)
Other versions
JP7880290B2 (ja
JP2023503046A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/061223 external-priority patent/WO2021102107A1/en
Publication of JP2023503046A publication Critical patent/JP2023503046A/ja
Publication of JP2023503046A5 publication Critical patent/JP2023503046A5/ja
Application granted granted Critical
Publication of JP7880290B2 publication Critical patent/JP7880290B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022529007A 2019-11-19 2020-11-19 ポンペ病およびリソソーム障害を処置するための肝臓特異的プロモーターを含む治療用アデノ随伴ウイルス Active JP7880290B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962937556P 2019-11-19 2019-11-19
US201962937583P 2019-11-19 2019-11-19
US62/937,556 2019-11-19
US62/937,583 2019-11-19
US202063023570P 2020-05-12 2020-05-12
US63/023,570 2020-05-12
PCT/US2020/061223 WO2021102107A1 (en) 2019-11-19 2020-11-19 Therapeutic adeno-associated virus comprising liver-specific promoters for treating pompe disease and lysosomal disorders

Publications (3)

Publication Number Publication Date
JP2023503046A JP2023503046A (ja) 2023-01-26
JP2023503046A5 true JP2023503046A5 (cg-RX-API-DMAC7.html) 2023-11-28
JP7880290B2 JP7880290B2 (ja) 2026-06-25

Family

ID=75981066

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022529007A Active JP7880290B2 (ja) 2019-11-19 2020-11-19 ポンペ病およびリソソーム障害を処置するための肝臓特異的プロモーターを含む治療用アデノ随伴ウイルス

Country Status (12)

Country Link
US (1) US20230038520A1 (cg-RX-API-DMAC7.html)
EP (1) EP4061946A4 (cg-RX-API-DMAC7.html)
JP (1) JP7880290B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220098384A (cg-RX-API-DMAC7.html)
CN (1) CN116096895A (cg-RX-API-DMAC7.html)
AU (1) AU2020388634A1 (cg-RX-API-DMAC7.html)
CA (1) CA3159018A1 (cg-RX-API-DMAC7.html)
IL (1) IL293068A (cg-RX-API-DMAC7.html)
MX (1) MX2022005916A (cg-RX-API-DMAC7.html)
PH (1) PH12022551229A1 (cg-RX-API-DMAC7.html)
TW (1) TWI920044B (cg-RX-API-DMAC7.html)
WO (1) WO2021102107A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020533968A (ja) * 2017-08-25 2020-11-26 オービッド・セラピューティクス・インコーポレイテッドOvid Therapeutics Inc. 組換えアデノ随伴ベクター
WO2020102645A1 (en) * 2018-11-16 2020-05-22 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus for treating pompe disease
US20240287148A1 (en) * 2021-07-15 2024-08-29 Cornell University Engineered biomolecules for nutrient reprogramming
WO2023028567A2 (en) * 2021-08-25 2023-03-02 Canbridge Pharmaceuticals, Inc. Aav particles comprising a liver-tropic capsid protein and acid alpha-glucosidase (gaa) and their use to treat pompe disease
EP4392569A4 (en) * 2021-08-25 2025-07-16 Canbridge Pharmaceuticals Inc AAV PARTICLES COMPRISING A LIVER-TROPIC CAPSID PROTEIN AND AN ALPHA-GALACTOSIDASE AND THEIR USE FOR TREATING FABRY DISEASE
CN117535291A (zh) * 2021-09-08 2024-02-09 北京锦篮基因科技有限公司 一种高表达活性的组成型启动子及其应用
CA3248631A1 (en) * 2022-01-21 2023-07-27 AstraZeneca Ireland Limited GENE THERAPY FOR GAUCHER'S DISEASE
KR20240145491A (ko) * 2022-02-03 2024-10-07 아스텔라스 진 테라피스, 인크. 폼페병의 개선된 치료를 위한 조성물 및 방법
CA3252501A1 (en) * 2022-02-25 2023-08-31 AskBio Inc. Adeno-associated virus therapy for the treatment of Pompe disease with long-term cessation of GAA enzymatic replacement therapy
WO2023172975A1 (en) * 2022-03-08 2023-09-14 University Of Massachusetts Methods of raav packaging
EP4493703A4 (en) * 2022-03-18 2026-08-05 Univ Florida METHODS AND COMPOSITIONS FOR TREATING TMEM43-RELATED CARDIOMYOPATHY WITH A VIRAL VECTOR
CA3254578A1 (en) * 2022-03-18 2023-09-21 AskBio Inc. Adeno-associated virus therapy involving an alpha-glucosidase (GAA) codon-optimized nucleic acid to treat Pompe disease, with signal peptide modifications
WO2024055272A1 (zh) * 2022-09-16 2024-03-21 复旦大学附属中山医院 能高效表达目的基因的mRNA载体系统、其构建及应用
WO2024212961A1 (en) * 2023-04-10 2024-10-17 Skyline Therapeutics (Shanghai) Co., Ltd. Recombinant aav for the gene therapy of pompe disease
CN121311595A (zh) 2023-04-17 2026-01-09 阿斯克生物公司 转基因在灵长类动物中可调节的受控表达
JP2026516710A (ja) * 2023-04-20 2026-05-26 アスクバイオ インコーポレイテッド 肝臓特異的調節核酸配列
KR20240159745A (ko) 2023-04-28 2024-11-06 아주대학교산학협력단 유산균 유래 nadh 산화효소를 이용한 비알코올성 지방간염의 유전자 치료제
KR102814185B1 (ko) * 2023-07-20 2025-06-12 제닉스큐어 주식회사 라포라병을 예방 또는 치료하기 위한 재조합 아데노 연관 바이러스 및 이를 포함하는 약학적 조성물
WO2025018822A1 (ko) * 2023-07-20 2025-01-23 제닉스큐어 주식회사 라포라병을 예방 또는 치료하기 위한 재조합 아데노 연관 바이러스 및 이를 포함하는 약학적 조성물
IL326018A (en) * 2023-07-28 2026-03-01 Regeneron Pharma Introduction of anti-TFR:GAA and anti-CD63:GAA for the treatment of Pompe disease
EP4786601A1 (en) 2025-01-31 2026-08-05 AskBio Inc. Helper plasmids and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001266740A1 (en) * 2000-06-06 2001-12-17 Genelabs Technologies, Inc. Promoters for regulated gene expression
PT1587923E (pt) * 2003-01-22 2011-12-07 Univ Duke Construções melhoradas para a expressão de polipéptidos lisossomais
US7521211B2 (en) * 2005-04-05 2009-04-21 Regeneron Pharmaceuticals, Inc IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof
MX2009012609A (es) * 2007-05-22 2009-12-07 Amgen Inc Composiciones y metodos para producir proteinas de fusion bioactivas.
WO2009137721A2 (en) * 2008-05-07 2009-11-12 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
US9206401B2 (en) * 2010-12-22 2015-12-08 Fondazione Telethon Therapeutic strategies to treat CNS pathology in mucopolysaccharidoses
SG10201605874TA (en) * 2011-04-22 2016-09-29 Genzyme Corp Modified acid alpha glucosidase with accelerated processing
AU2016366549B2 (en) * 2015-12-11 2022-11-10 California Institute Of Technology Targeting peptides for directing adeno-associated viruses (AAVs)
KR102617502B1 (ko) * 2016-09-12 2023-12-26 제네똥 산-알파 글루코시다제 변이체 및 이의 용도
EP3293260A1 (en) * 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293259A1 (en) * 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
AU2018281280B2 (en) * 2017-06-07 2024-12-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
CN111936621B (zh) * 2018-02-05 2025-05-13 奥登茨治疗公司 转录调控元件和它的用途
CN112040985A (zh) * 2018-02-07 2020-12-04 瑞泽恩制药公司 用于递送治疗性蛋白质的方法和组合物
TW202344691A (zh) * 2018-04-30 2023-11-16 美商阿米庫斯醫療股份有限公司 基因治療構築體及使用方法
WO2020102645A1 (en) * 2018-11-16 2020-05-22 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus for treating pompe disease

Similar Documents

Publication Publication Date Title
US20260083862A1 (en) Methods and compositions for treating brain diseases
US20230048025A1 (en) Adeno associated viral vectors
JP7654562B2 (ja) 線維芽細胞増殖因子23関連低リン血症性疾患の遺伝子療法
CA2243261C (en) Methods for delivering dna to muscle cells using recombinant adeno-associated virus virions
CN113316639A (zh) 用于治疗庞贝氏病的治疗性腺相关病毒
JP2022520232A5 (cg-RX-API-DMAC7.html)
IL299325B1 (en) Variants of acid alpha-glucosidase and their uses
IL293068A (en) A therapeutic adeno-associated virus containing liver-specific promoters for the treatment of Pompe disease and lysosomal disorders
WO2023060269A4 (en) Recombinant adeno-associated viruses for targeted delivery
JP2024523707A5 (cg-RX-API-DMAC7.html)
JP2022513308A5 (cg-RX-API-DMAC7.html)
JP2021533805A5 (cg-RX-API-DMAC7.html)
EP4048786A1 (en) Chimeric polypeptides and uses thereof
JP2023539247A (ja) Glp-1受容体アゴニスト融合物をコードするウイルスベクター及びネコの代謝性疾患の治療におけるその使用
JP2024515902A5 (cg-RX-API-DMAC7.html)
JP2025510017A5 (cg-RX-API-DMAC7.html)
CN119173269A (zh) 用于递送glp-1受体激动剂融合物的aav载体
KR20240167720A (ko) 인슐린 융합 단백질을 암호화하는 바이러스 벡터 게놈
IL315711A (en) Therapeutic adeno-associated virus using codon optimized nucleic acid encoding alpha-glucosidase (gaa) for treating pompe disease, with signal peptide modifications
JP2008504001A (ja) サイトカイン変異体ポリペプチド
JP2025504478A5 (cg-RX-API-DMAC7.html)
WO2021078834A1 (en) Chimeric acid-alpha glucosidase polypeptides and uses thereof
HK40098913A (en) ENGINEERED α-GAL A PEPTIDES AND FUNCTIONAL VARIANTS THEREOF AND ASSOCIATED METHODS OF TREATING FABRY DISEASE
HK40098913B (en) ENGINEERED α-GAL A PEPTIDES AND FUNCTIONAL VARIANTS THEREOF AND ASSOCIATED METHODS OF TREATING FABRY DISEASE
CN116376921A (zh) 一种用于治疗糖尿病的aav载体及其用途